奈达铂联合方案二线治疗肺癌近期疗效观察  

Clinical observation of short-term effects of nedaplatin-based chemotherapy in second-line treatment of lung carcinomas

作　　者：汪宏斌[1] 杨俊泉[1] 王翠兰[1] 

机构地区：[1]唐山市人民医院放化科,河北唐山063001

出　　处：《现代肿瘤医学》2012年第12期2529-2531,共3页Journal of Modern Oncology

摘　　要：目的:观察奈达铂联合多西紫杉醇方案治疗非小细胞肺癌以及奈达铂联合伊立替康方案治疗小细胞肺癌的近期疗效和不良反应。方法:选择一线化疗失败的26例晚期非小细胞肺癌和6例小细胞肺癌。非小细胞肺癌患者采用多西紫杉醇联合奈达铂方案(DN方案),小细胞肺癌患者接受伊立替康联合奈达铂方案(IN方案)。DN方案:奈达铂80mg/m2,加入生理盐水500ml第1天静滴,多西紫杉醇75mg/m2第1天静脉滴注。IN方案:伊立替康60mg/m2第1、8天静脉滴注,奈达铂50mg/m2第1、8天静脉滴注。所有方案均为每21天为1个周期,治疗2-4个周期。评价化疗的近期疗效和不良反应。结果:总有效率为21.9%(7/32),无完全缓解者,部分缓解21.9%(7/32),稳定65.6%(21/32),进展12.5%(4/32)例,疾病控制率为87.5%(28/32)。中位总生存期OS 14个月,1年OS生存率53.1%(17/32);中位无进展生存期PFS为11个月,1年PFS生存率34.4%(11/32)。主要不良反应为Ⅰ-Ⅱ度骨髓抑制、恶心呕吐。结论:奈达铂联合多西紫杉醇、伊立替康治疗肺癌疗效可,不良反应可以耐受。Objective：To investigate the short-term therapeutic effects and adverse events of nedaplatin-based chemotherapy in second-line treatment of lung carcinomas.Methods： Twenty-six advanced non-small lung cancer（NSCLC） and six small cell lung cancer（SCLC） patients who failed first-line chemotherapy were enrolled.The NSCLC group was treated by docetaxel combined with nedaplatin chemotherapy（DN regimen）,whereas the SCLC group treated by irinotecan combined with nedaplatin（IN regimen）.In DN regimen,patients received 75mg/m2 of docetaxel intravenously at the first day,followed by 80mg/m2 of nedaplatin intravenously at the first day.In IN regimen,patients were administered 60 mg/m2 of irinotecan and 50 mg/m2 of nedaplatin intravenously on day 1,8.All regimens repeated every 21 days from 2 cycles to 4 cycles.The short-term therapeutic effects and adverse events after chemotherapy were evaluated.Results： The overall response rate was 21.9%（7/32）,with no complete response,21.9%（7/32） partial response,and 65.6%（21/32） stable disease,and 12.5%（4/32） progression disease.The overall disease control rate was 87.5%（28/32）.The median overall survival（OS） was 14 months,1-year OS 53.1%（17/32）.The median progression free survival（PFS） was 11 months,1-year PFS 34.4%（11/32）.The main adverse events were grade Ⅰ-Ⅱ bone marrow suppression,grade Ⅰ-Ⅱ nausea and vomiting.Conclusion： Combined nedaplatin with docetaxel or irinotecan in second-line treatment of lung carcinomas is effective and tolerated by patients with relapse lung cancer.

关 键 词：肺癌 化疗 奈达铂 多西紫杉醇 伊立替康 

分 类 号：R734.2[医药卫生—肿瘤]